[Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC].

Martin Wilhelm^* (First author)

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

Original language	German
Pages (from-to)	691-692
Journal	STRAHLENTHERAPIE UND ONKOLOGIE
Volume	195
Issue number	7
DOIs	https://doi.org/10.1007/s00066-019-01456-3
Publication status	Published - 2019

Access to Document

@article{ebf58bdb7ae84b368cd691c0042695a7,

title = "[Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC].",

author = "Martin Wilhelm",

note = "Wilhelm: Paracelsus Med Privatuniv, Univ Klin Innere Med 5, Klinikum Nurnberg, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany",

year = "2019",

doi = "10.1007/s00066-019-01456-3",

language = "Deutsch",

volume = "195",

pages = "691--692",

journal = "STRAHLENTHERAPIE UND ONKOLOGIE ",

issn = "0179-7158",

publisher = "Springer Nature",

number = "7",

}

Research output: Contribution to journal › Editorial › peer-review

TY - JOUR

T1 - [Durvalumab after chemoradiotherapy is currently the most promising treatment for stage III NSCLC].

AU - Wilhelm, Martin

N1 - Wilhelm: Paracelsus Med Privatuniv, Univ Klin Innere Med 5, Klinikum Nurnberg, Prof Ernst Nathan Str 1, D-90419 Nurnberg, Germany

PY - 2019

Y1 - 2019

U2 - 10.1007/s00066-019-01456-3

DO - 10.1007/s00066-019-01456-3

M3 - Editorial

C2 - 30949719

SN - 0179-7158

VL - 195

SP - 691

EP - 692

JO - STRAHLENTHERAPIE UND ONKOLOGIE

JF - STRAHLENTHERAPIE UND ONKOLOGIE

IS - 7

ER -